Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III grass pollen SLIT tablet study started 2 months before pollen season
2008-003906-32Phase 3Completed
- Sponsor
- Stallergenes Greer
- Start
- Sep 2008
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) and allergic rhinitis (AR) comparing Grass pollen allergen extract 300 IR with Placebo (2 arms). Primary endpoint: Average Adjusted Symptom Score. Started Sep 2008; status: completed.
02
Drugs
Oralair
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic rhinitis (AR)
Beyond the preview
Go deeper on 2008-003906-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003906-32.